German Researchers Find Sensitizer for Gemcitabine Using DECIPHER RNAi Libraries

June 10, 2013

Researchers at the German Cancer Research Center (DKFZ) used Cellecta's shRNA DECIPHER libraries to identify genes that sensitize pancreatic cells to gemcitabine.Pancreatic cancer has only a 6% 5-year survival rate. Gemcitabine is the standard treatment in conjunction with surgery to remove cancerous...
Read More

Second Phase SBIR Contract from the National Cancer Institute (NCI) to Identify Lethal Gene Combinations in Cancer Cell Models

October 23, 2012

It's been a while since the last post to this blog. It is not that nothing has been going on, in fact, quite the opposite. It has been quite busy the past several months and, unfortunately, blog postings have suffered. However, I thought I would get things started again with short post about our recent SBIR...
Read More

Tissue Targeting May Offer an Alternative Therapeutic Approach for Difficult-to-Treat Diseases

October 14, 2011

We recently received a phase II of our SBIR grant Exploiting Synthetic Lethality of Hematopoietic Lineage Cells to Develop Novel Targets from the NIH. Rather than trying to identify potential drug targets in oncogenic hematopoietic cells, much of the effort for this project focuses on trying to develop a...
Read More